Navigation Links
Older women's heart health depends on location of fat

A new study by researchers in Denmark has shown that, it is not the amount of fat that matters but the distribution of the fat that is important, when it comes to the heart health of women over 60. The study involved a group of 1,356 women aged between 60 and 85 whose body fat distribution and amount of atherosclerosis in the abdominal part of the aorta was measured. Atherosclerosis in the abdominal part of the aorta is an assessment of the degree of fatty build up in// the arteries. The women were divided into four groups which consisted of lean women, women with low central fat and high peripheral fat, women with high central fat and low peripheral fat, and obese women with high levels of both kinds of fat. Central fat is carried around the abdomen while peripheral fat is found on the arms, legs, buttocks, and hips. Central fat has already been shown to be a health risk.

Researchers found that obese women had suprisingly less atherosclerosis than expected while women with high central fat and low peripheral fat had the most atherosclerosis, as well as high blood sugar and high cholesterol. Women with more peripheral and less central fat had the best blood sugar metabolism suggesting that peripheral fat had a protective role and behaved differently from central fat.


'"/>




Page: 1

Related medicine news :

1. Older men father schizophrenics
2. Creatine Helps Strengthen Older Men
3. Older Men Surviving Coronary Bypasses
4. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
5. Frailty in Older Women may be due to Chronic Infection
6. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
7. Older People May Not Need Multivitamins To Prevent Infections
8. Gene Variation Associated With Better Mobility For Older Individuals
9. Older People Can Also Eat As Young!
10. Safe Driving Is Possible For Older People If They Are Prepared
11. Tarceva Found To Benefit Older Lung Cancer Patients
Post Your Comments:
(Date:5/15/2008)... AARP commends Governor Paterson,s leadership...nd transparency, ALBANY, N.Y., May 15 /PRNewswire...s a paramount interest in passing the Governor,s p...ss the undue influence that,pharmaceutical compani...,only consumers, pocket books but the treatment th...
(Date:5/15/2008)... , WASHINGTON, D.C. -- May 15, 2008 -- The Socie...s (SCAI) today announced that it will hold its 200...sars Palace, Las Vegas. The focused, collegial int... February or early March meeting time beginning in...s will be the premier interventional cardiology me...
(Date:5/15/2008)... OAKLAND, Calif., May 15 /PRNewswire-FirstCal...tion (the "Company") today announced that, on May,...tion Letter stating that,the Company,s requests fo...as been denied. The NASDAQ noted that the Company ...bility to achieve near term compliance with,the co...
(Date:5/15/2008)... PRINCETON, N.J., May 15 /PRNewswire-FirstCal...l stage pharmaceutical company committed to,discov...to treat viral,infections, reported unaudited fina...March 31, 2008. Pharmasset reported a net loss att... or ($0.57) per share for the,quarter ended March ...
Breaking Medicine News(10 mins):Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
...ow about 10 percent of women in their mid-20s and ...ent. Women with poor memory // skills are also of... supplements may reverse memory loss in these wome...between ages 18 and 35. The women were either anem...
...ch shows calcium from milk, supplements, or other ... promoting weight loss ,// so if your mother alway...er, she may have been wrong. Participants in the...re weight. Researchers say if the body consumes en...
... a treatment plan for Leukemia , doctors rely on i...ikely to be, // including how the cancer cells loo...se history. However, for some patients, those indi... high-risk or low-risk group. Doctors may be left ...
...troke happens when a clot blocks blood flow to the...o function on their own. //Now, a new study shows ...a stroke appear to regain more functional independ... study, researchers evaluated the outcomes of 167 ...
Other Medicine News:
(Date:5/15/2008)...- Sanofi-aventis,(EURONEXT:...from the,landmark ATHENA study showed Multaq(R) (d... of patients with atrial fibrillation or atrial fl...alizations or death from any,cause by a statistica...udy,primary endpoint. The ATHENA results will be p...
(Date:5/15/2008)... -- CenterWatch, a publishing and,information serv...ical,trials, finds that investigative sites are re...ure) systems. More than 75% of respondents to a re...en trained on three or more,EDC systems. In additi...,their EDC training had improved., State of the C...
(Date:5/15/2008)...ice Plan Positions Blue Cross Blue Shield of ...eport from HealthLeaders-In...- HealthLeaders-InterStudy, the,leading provider o...s the,economy continues to stagnate in Michigan, B... equipped of all of its competitors to weather the...
(Date:5/15/2008)...Newswire/ -- Omega 3 fatty acids bound to,phosphol...ble natural,alternative and may have beneficial ef...vo French study reveals. While several studies hav...ctivity, French researchers have,hypothesized that... on,impulse control., These research findings hav...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Hospitals See Infection Rates More Than Halved Patient Stays Shortened by 27 Percent in New Study Announced by I Flow 1532 1Hospitals See Infection Rates More Than Halved Patient Stays Shortened by 27 Percent in New Study Announced by I Flow 1532 2Hospitals See Infection Rates More Than Halved Patient Stays Shortened by 27 Percent in New Study Announced by I Flow 1532 3Hospitals See Infection Rates More Than Halved Patient Stays Shortened by 27 Percent in New Study Announced by I Flow 1532 4Hospitals See Infection Rates More Than Halved Patient Stays Shortened by 27 Percent in New Study Announced by I Flow 1532 5Hospitals See Infection Rates More Than Halved Patient Stays Shortened by 27 Percent in New Study Announced by I Flow 1532 6Onyx Pharmaceuticals to Present at UBS Global Life Sciences Conference 660 1Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 655 1Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 655 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 655 3Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 655 4Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 655 5Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 655 6Eating competence may lower risk of heart disease 442 1Eating competence may lower risk of heart disease 442 2
... WIRE)--May 10, 2007 - An evaluation of the,safety...py for the,treatment of vaginal atrophy, a frequen... released by The North American,Menopause Society ...en for treatment of vaginal atrophy in postmenopau...erican Menopause Society,",the document was develo...
...sentation for Pristiq Occurs at the 55th Annual,Cl...cians and,Gynecologists, COLLEGEVILLE, Pa., May 09...cals, a division of Wyeth , presented results from...(desvenlafaxine) for,the treatment of moderate-to-...weats) associated with menopause. These studies sh...
Other Medicine Technology:New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 2New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 2Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 4Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 5Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 6
Intended for the quantitative determination of alphaamylase activity in serum. Single vial, dry powder reagent. Reaction: Kinetic. Wavelength: 405 nm. Linearity: 2000 U/L at 37C.
For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl.
For the quantitative determination of alanine aminotransferase in human serum.
Intended for the quantitative determination of alanine aminotransferase activity in serum or plasma. Liquid buffer and dry powder reagent. Pyridoxal Phosphate tablets must be purchased separately for
Medicine Products: